Cyclic Depsipeptide Synthesis via Segmented Solid-Phase and Solution-Phase Routes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing methods for producing cyclic depsipeptides, such as those used for treating inflammatory and hyperproliferative skin diseases, face challenges in achieving high yield and purity due to risks like epimerization and tautomerization, and require complex synthesis processes involving solid phase peptide synthesis and solution phase reactions.
Innovation Solution
A method combining solid phase peptide synthesis with solution phase reactions, including selective deprotection, oxidation under specific conditions, and controlled lactamization, to produce cyclic depsipeptides with improved yield and stereoisomeric purity, involving the conversion of by-products like dehydro-ahp substructures into desired products.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If fermentation is used to produce cyclic depsipeptides, then the process is simple and uses natural production, but the yield is rather low
Solution Approach 1:
The synthesis is divided into modular stages: solid phase peptide synthesis for the peptide chain, solution phase for the ahp-substructure formation, and final cyclization. This segmentation allows optimization of each stage independently, achieving high yield while maintaining process manageability.
Solution Approach 2:
The peptide chain is pre-assembled on solid phase support with protected functional groups before final cyclization. This preliminary assembly with protected groups prevents unwanted side reactions during chain formation, enabling high yield in the final cyclization step.
2Manufacturing precision
If complex synthesis processes are used to avoid epimerization and tautomerization, then stereoisomeric purity is improved, but the device complexity increases
Solution Approach 1:
Protecting groups are installed on all reactive functional groups before peptide assembly and cyclization. This preliminary protection prevents epimerization and tautomerization during synthesis, ensuring stereoisomeric purity without requiring complex process controls.
Solution Approach 2:
Solid phase support acts as an intermediary that stabilizes the peptide chain during assembly. The solid phase enables controlled coupling reactions that maintain stereochemical integrity while simplifying purification and preventing racemization.
3Ease of manufacture
If by-products are not converted, then the synthesis process is simpler, but the yield is reduced
Solution Approach 1:
By-products containing dehydro-ahp substructures or five-membered ring analogues are converted into the desired ahp-containing cyclic depsipeptides through acid-catalyzed rearrangement. This converts harmful by-products into beneficial additional product, increasing overall yield while adding only a simple acid treatment step.
4Manufacturing precision
If selective deprotection and controlled oxidation are used, then purity is improved, but the use of energy and time increases
Solution Approach 1:
Protecting groups serve as intermediaries that are selectively removed at specific stages. The orthogonal protection strategy allows selective deprotection under mild conditions, maintaining purity while minimizing energy input and reaction time compared to harsh deprotection methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the yield and purity of cyclic depsipeptides, reducing by-products and avoiding issues like epimerization, thereby improving the efficiency of the synthesis process.
Implementation Method 1
reacting the free hydroxyl group under oxidizing conditions to form a compound of the formula IV
Data Source
AI summary
The invention relates to a method or process for the chemical manufacture of depsipeptides of the formula I,wherein the symbols have the meaning defined in the description, to new intermediates and their manufacture, as well as related invention embodiments.